Cancer / Oncology
NCCN and Vietnam National Cancer Hospital Unite to Elevate Cancer Care Standards Across Vietnam
As part of ongoing work to define and advance high-quality cancer care globally, leaders from the National Comprehensive Cancer Network® (NCCN®...
November 01, 2024 | News
Hong Kong’s Akeso Biopharma Enrolls First Patient in Pioneering Phase III Trial for Advanced Head and Neck Cancer Therapy
Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (A...
October 31, 2024 | News
RiboX Therapeutics Secures FDA IND Clearance for First Circular RNA Therapy, Initiating Clinical Trials for RXRG001
RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, ...
October 28, 2024 | News
Pierre Fabre Doses First Patient with PFL-002/VERT-002, a Novel c-MET Degrader for MET-Altered Cancers
PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET, with the potential to be...
October 25, 2024 | News
RAPT Therapeutics Boosts Drug Development Efficiency with INTEGRA Biosciences’ Pipettes for Cancer and Inflammatory Disease Research
RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small...
October 23, 2024 | News
GE HealthCare Launches AI-Powered CareIntellect for Oncology to Streamline Cancer Treatment Insights
Application goes beyond data aggregation to help clinicians quickly see a longitudinal view of their patient’s history, spotlighting disease ...
October 22, 2024 | News
Thermo Fisher’s Oncomine Dx Target Test Receives FDA Approval to Guide Treatment with Servier’s VORANIGO® for Grade 2 IDH-Mutant Glioma
Oncomine Dx Target Test to Identify Patients Eligible for Servier’s VORANIGO® (vorasidenib) tablet, the only FDA-approved treatment for Grade 2 I...
October 22, 2024 | News
LaNova Medicines Initiates Phase 1 Trial of Anti-PD-1/VEGF BsAb LM-299 in China for Advanced Solid Tumors
Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstra...
October 21, 2024 | News
Tencent Invests US$30 Million in Hong Kong’s Insighta, Valuing the Early Cancer Detection Company at US$200 Million
Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, announced that Tencent has made a strategic US$30 million&n...
October 16, 2024 | News
Pierre Fabre and Scorpion Therapeutics Dose First Patient in Phase I/II Trial of PFL-241/STX-241, a Promising 4th Generation EGFR Inhibitor
PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR...
October 09, 2024 | News
MediLink Therapeutics and Amgen Announce Global Clinical Collaboration to Evaluate Combination Therapy for Extensive-Stage Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, announced a global clinical trial collaboration and supply agreeme...
October 08, 2024 | News
Telix Pharmaceuticals Secures TGA Approval for Illuccix® to Select Patients for PSMA-Targeted Radionuclide Therapy
Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the us...
October 08, 2024 | News
Innovent Biologics and ASK Pharm Announce Strategic Partnership to Commercialize Limertinib for EGFR-Mutated Lung Cancer in China
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
October 08, 2024 | News
Ascentage Pharma’s APG-2449 Tyrosine Kinase Inhibitor Cleared for Two Registrational Phase III Studies in NSCLC Patients
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet med...
October 08, 2024 | News
Most Read
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
